Department of Surgery, University of California, San Francisco, CA.
Transplantation. 2020 Feb;104(2):285-292. doi: 10.1097/TP.0000000000002783.
Alcoholic liver disease (ALD) accounts for 15%-30% of transplants performed in the United States and Europe; however, the data on living donor liver transplantation (LDLT) for ALD remain sparse. The purpose of this study was to examine the outcomes following LDLT for ALD using data from the adult-to-adult living donor liver transplantation (A2ALL) study, which represents the largest Western experience with adult-to-adult LDLT.
A retrospective review of A2ALL data collected between 1998 and 2014 was performed. Patients were excluded if they received a deceased donor liver transplant. Demographic data, postoperative outcomes and complications, graft and patient survival, and predictors of graft and patient survival were assessed.
Of the 1065 patients who underwent LDLT during the study time period, 168 (15.8%) were transplanted for a diagnosis of ALD. Comparing patients who underwent transplant for ALD with those who were transplanted for other etiologies of liver disease, there was no significant difference in graft survival at 1 (88% versus 84%), 5 (76% versus 74%), or 10 years following transplant (55% versus 61%, P = 0.29). Similarly, there was no difference in patient survival at 1 (94% versus 91%), 5 (83% versus 79%), or 10 years following transplant (61% versus 66%, P = 0.32).
LDLT for ALD results in excellent 1-, 5-, and 10-year graft and patient survival. Patients with ALD and impaired renal function have a higher risk of graft loss and death. These findings support the notion that early LDLT for patients with ALD may help optimize outcomes.
在美国和欧洲,酒精性肝病(ALD)占肝移植的 15%-30%;然而,关于ALD 活体肝移植(LDLT)的数据仍然很少。本研究的目的是使用成人对成人活体肝移植(A2ALL)研究的数据来检查 LDLT 治疗 ALD 的结果,该研究代表了最大的西方成人对成人 LDLT 经验。
对 1998 年至 2014 年间收集的 A2ALL 数据进行回顾性分析。排除接受已故供体肝移植的患者。评估人口统计学数据、术后结果和并发症、移植物和患者存活率以及移植物和患者存活率的预测因素。
在研究期间,有 1065 例患者接受 LDLT,其中 168 例(15.8%)诊断为 ALD。将接受移植治疗 ALD 的患者与接受其他病因肝脏疾病的患者进行比较,移植后 1 年(88%对 84%)、5 年(76%对 74%)和 10 年(55%对 61%)的移植物存活率无显著差异(P=0.29)。同样,移植后 1 年(94%对 91%)、5 年(83%对 79%)和 10 年(61%对 66%)的患者存活率也无差异(P=0.32)。
LDLT 治疗 ALD 可获得优异的 1 年、5 年和 10 年移植物和患者存活率。患有 ALD 和肾功能受损的患者移植物丢失和死亡的风险更高。这些发现支持这样一种观点,即早期 LDLT 治疗 ALD 患者可能有助于优化结局。